So, in order to focus on company communication, or lack of it, lets devise a list: the top ten questions we'd like answered by Biota management. Here's 9 to start:

1. Vapendavir has had over 20 million dollars spent on its development. You are still considering its future. Why? What are the issues that you need to clarify to determine the next step? Who is considering those issues? How long will considering those issues take? Have you had any interest in this compound? Why was a Phase 2b trial initiated? How much longer does this compound have on its patent?

2. What are the legacy issues in using Nabi as the vehicle for a reverse takeover and listing vehicle?

3. You are reassembling your team at Inhibitex. We can understand the advantages in doing that, but what are the disadvantages?

4.Why do you have so many Board members?

5. You have a significant number of Australian shareholders. Is that now irrelevant? Does that influence your communication strategy? Will you hold shareholder and analyst meetings in Australia? Is dual listing on the ASX a possibility to assist current and potential shareholders to manage their holdings from Australia?

6. The arrangement with Daiichi Sankyo for Rest of World rights and royalties to lananimavir is opaque, and may be negatively affecting the market's view and valuation of the company. When will this be finalised? Why would the company delay finalising this arrangement given the impact on the company's valuation?

7. It was the previous management's intention to take LANI to market in the ROW. What is your view?

8. There has been no positive reaction from the market to the NASDAQ listing and recent strategic review. The BOTA shareprice is poor, while the US market is reaching new highs. Why? What would be the drivers of shareprice improvement in BOTA? What would US institutional investors seek in a biotech like BOTA before investing?